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Abstract—To identify possible intracellular mediators of hair
cell (HC) death due to ototoxins, we treated basal-turn, neo-
natal, rat HCs in vitro with several intracellular signaling
inhibitors, prior to and during gentamicin exposure. The gen-
eral guanine nucleotide-binding protein (G-protein) inhibitor,
GDP-S (1 mM), provided potent HC protection, suggesting
involvement of G-proteins in the intracellular pathway linking
gentamicin exposure to HC death. ADP-S had minimal ef-
fect, indicating that the protection is specific to guanosine
diphosphate (GDP)-binding, rather than a general reaction to
nucleotides. Azido-GTP32 photolabeling and gel electro-
phoresis indicated activation of an approximately 21 kDa
G-protein in HCs after exposure to gentamicin. Spectro-
scopic analysis of peptide fragments from this band matched
its sequence with H-Ras. The Ras inhibitors B581 (50 M) and
FTI-277 (10 M) provided potent protection against damage
and reduced c-Jun activation in HC nuclei, suggesting that
activation of Ras is functionally involved in damage to these
cells due to gentamicin. © 2003 IBRO. Published by Elsevier
Ltd. All rights reserved.
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Significant hearing loss occurs in about 10% of the popu-
lation, and in its severe form can produce devastating
isolation. In contrast to conductive hearing loss, which is
produced by pathologies in the external and/or middle ear,
sensorineural hearing loss (SNHL) is associated with dam-
age to cochlear hair cells (HCs) or neurons. Because HCs
are the most vulnerable elements in the cochlea, damage
to them underlies most forms of SNHL.
SNHL can result from a variety of causes, including
genetic disorders, infectious disease, overexposure to in-
tense sound and certain drugs. The most prevalent cause
of SNHL is aging. SNHL is often progressive, and mostly
irreversible. During the past several years, significant
progress in understanding SNHL has been made (see
Ding et al., 1999; Shulman, 1999; Ryan, 2000 for reviews).
Oxidative stress with the production of free radicals
(Schacht, 1999; Sha et al., 2001), activation of stress
pathways (Pirvola et al., 2000) and apoptosis (Huang et
al., 2000), have been implicated in HC damage and death.
Recently it has been demonstrated that c-Jun-N-termi-
nal kinases (JNK) are activated in HCs after gentamicin
exposure and that an inhibitor of mixed-lineage kinase,
upstream activators of JNKs, protected HCs from toxicity
(Pirvola et al., 2000). The JNKs are a member of the
mitogen-activated group of protein kinases (MAPKs) that
are important signal transducing enzymes involved in
many facets of cellular regulation including apoptosis
(Chang and Karin, 2001). However, intracellular signals
that lead to JNK activation in HCs have yet to be defined.
Among the elements leading to JNK activation in other
cells are the guanine nucleotide-binding proteins (G-pro-
teins). For example, activation of Ras in certain cell types
has been shown to be sufficient to activate JNK (Rausch
and Marshall, 1997). Members of the Rho family including
Rho, Rac and Cdc42 have also been implicated in JNK
activation (Bagrodia et al., 1995; Minden et al., 1995). In
addition, direct activation of G-proteins by free radicals has
been described in other cell systems (Perez-Sala and
Rebollo, 1999) and there are substantial data linking G-
proteins with apoptosis (Mayo et al., 1997). In this study we
addressed the role of GTPases in gentamicin-induced tox-
icity signaling.
EXPERIMENTAL PROCEDURES
Tissue culture
Explants of sensory epithelium from the basal cochlear turn of
postnatal day 5 (p5) Sprague–Dawley rats were isolated using the
methods of Van De Water and Sobkowicz (Van de Water and
Ruben, 1974; Sobkowicz et al., 1993). Explants were maintained
in Dulbecco’s Modified Eagle’s medium (DMEM) with 10% fetal
bovine serum (FBS) and 30 U/ml penicillin, to which HEPES buffer
had been added to a concentration of 25 mM to stabilize pH and
the glucose concentration increased to 6 mg/ml to enhance neu-
ronal survival (Gibco, BRL, Grand Island, NY, USA). Each 15 mm
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ulated kinase; FBS, fetal bovine serum; Ftase, farnesyl-transferase;
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dish containing 250 l of medium was maintained in an incubator
at 37 °C with 5% CO2 and 95% humidity. Gentamicin alone
cultures were maintained in this initial medium for 12–24 h and
then exposed to medium containing 35 M gentamicin (Sigma, St.
Louis, MO, USA) for 48 h. This concentration has been found to
result in approximately 50% loss of outer HCs (OHCs), and was
used to permit increases or decreases in OHC damage to be
detected. For all inhibitor studies, cultures were maintained over-
night (12 h) with a test substance. This was to permit the sub-
stance to penetrate the HC membrane. They were then chal-
lenged with medium containing 35 M gentamicin plus the test
substance for an additional 48 h, followed by fixation and evalu-
ation. The doses of test substances (Cal-Biochem, San Diego,
CA, USA; Sigma) employed were based on published 50% inhib-
itory concentrations (IC50) in other whole-cell systems: the farne-
syl-transferase (Ftase)-1-inhibitor B581 (5, 50 M); the more spe-
cific and cell-permeable Ftase inhibitor FTI-277 (1, 2, 5, 10,
25 M); GDP-S and ADP-S (1 M; Lerner et al., 1995; Ui et al.,
1995; Burke et al., 1996; Slee et al., 1996; Leonard, 1997; Eyers
et al., 1998; Humpf et al., 1998; Newton et al., 2000). GDP-S, a
competitive inhibitor of GTP, and ADP-S, a structurally similar
molecule that does not interact with GTP bindings sites, are
known to have low but similar permeabilities in intact cells after
3–4 h (Kuchan et al., 1994). U0126 (1,4-diamino-2,3-dicyano-1,4-
bis[2-aminophenylthio]butadiene) is cell permeable and a very
specific MEK inhibitor at micromolar concentrations. U0126 (IC50
approximately 1.0 M) has been shown not to inhibit protein
kinase C, Raf, MEKK, ERK, JNK, MKK3, 4, and 6, and Cdk2 and
4 (Alessi et al., 1995; Newton et al., 2000). U0126 was used at
1 M. We and others have shown this concentration to be non-
toxic to many cell types (e.g. Alessi et al., 1995; Newton et al.,
2000; Aletsee et al., 2001; Palacios et al., 2002). U0124 is a
structurally similar but inactive compound that is often used as a
control for U0126. The highest dose of each inhibitor used was
used in combination with 50 M gentamicin on E. coli cultures, as
a control for physical interaction with the antibiotic. None had any
effect on bactericidal activity (data not shown).
Phalloidin assays
At the end of culture, the free-floating explants were fixed with 4%
paraformaldehyde and 1% glutaraldehyde in phosphate-buffered
saline (PBS) for 45 min at 20 °C, then permeablized with 1%
Tween 20 (polyoxyethylene sorbitan monolaurate) in PBS at 20 °C
for 30 min. The explants were then stained with a conjugated
phalloidin-rhodamine probe in PBS at 20 °C for 45 min, washed
twice with PBS and mounted between two coverslips in a 1:3
mixture of PBS/glycerol. Phalloidin-rhodamine stains the F-actin
of the stereocilia and cuticular plate of viable HCs (Thorne et al.,
1987). It also lightly outlines the body of HCs by binding to the
actin that is associated with the inner surface of the cell membrane
(Thorne et al., 1987). Because one of the earliest signs of mor-
phologic injury is damage to stereocilia, it is readily detected by
phalloidin staining. Subsequent apical vacuolization, swelling of
the HC, damage to the cuticular plate and finally HC death can
also be observed (Raphael et al., 1994). The phalloidin assay has
been widely used to assess the integrity of HCs (Meiteles and
Raphael, 1994; Raphael et al., 1994). Explants were imaged by
light and fluorescence microscopy and by laser confocal
microscopy.
Assessment of HC survival
HCs were characterized as missing if no stereocilia or cuticular
plate in the appropriate location was observed. Quantitative re-
sults were obtained by evaluating the thirty OHCs associated with
10 inner HCs (IHCs) in a given microscope field. The average of
four separate counts was used to represent each culture and only
those cultures for which four separate counts could be obtained
were included in the study. Six cultures were used for each
condition tested.
Phospho-c-Jun immunhistochemistry
The basal turn of the organ of Corti (OC) was dissected and
cultured as described above. Gentamicin alone explants were
exposed to 35 M gentamicin for 20 h. Experimental cultures were
pretreated with FTI-277 (35 M) for 12 h, then with gentamicin and
FTI-277 for 20 h. Normal control explants were maintained in
culture medium alone. FTI-277 alone explants were maintained in
culture media containing 10 M FTI-277 alone. At the end of the
culturing period, the explants were fixed as described above,
permeabilized with 5% Triton X-100 in PBS with 10% FBS for 30
min. The explants were washed twice with PBS and incubated in
1% donkey serum, then immunostained with a polyclonal rabbit
anti-phospho-c-Jun antibody (Ser-73; 1:50; Cell-Signaling). The
explants were washed twice with PBS, and incubated with a FITC
conjugated donkey anti-rabbit IgG (1:100; Jackson Immunore-
search, Bar Harbor, ME, USA) for 2.5 h, washed twice with PBS
and stained with the conjugated phalloidin-rhodamine probe for
1 h, washed twice in PBS and visualized on a fluorescent micro-
scope with either red filter (for the phalloidin-rhodamine staining,
excitation/emission wavelength 596 nm/615 nm) or green filter (for
the FITC staining, excitation/emission wavelength 490 nm/
525 nm). The primary antibody was replaced with PBS as a
control for non-specific binding.
G-protein photoaffinity labeling, isolation and
sequence analysis
To determine whether ototoxins activate G-proteins, photoaffinity
labeling using a hydrolysis-resistant, photoaffinity GTP azido-an-
alog, guanosine 5-[32P] triphosphate [] 4-azidoanilide
([32P]GTP-AA) was employed. In photoaffinity G-protein label-
ing, a covalent linkage is created between the UV-sensitive,
[32P]GTP-AA probe and activated G-proteins, in which the GTP
analog occupies the GTP binding site. Thus, G-proteins that are
activated after exposure to ototoxins in cells loaded with the
[32P]GTP-AA probe can be irreversibly labeled and can subse-
quently be analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and autoradiography (Basu and
Modak, 1987). Once photolabeled, the proteins can also be puri-
fied through the use of immobilized metal (Fe3 or Al3) affinity
chromatography (IMAC). Immobilized Fe3 or Al3 selectively
binds phosphorylated proteins, including the photolabeled pro-
teins (Andersson and Porath, 1986). Once isolated, if sufficiently
pure, the proteins can be digested and identified using matrix-
assisted laser desorption ionization (MALDI) time-of-flight mass
spectrometry (Karas and Hillenkamp, 1988).
G-protein photolabeling
After incubation in serumless DMEM media for 1 h, five basal-turn
explants were permeabilized in the dark for 5 min at RT with
25 M digitonin in serumless media containing 10 Ci of
[32P]GTP-AA with a specific activity of 10–20 Ci/mmol. In sep-
arate explants, cells were checked for viability 12, 24 and 48 h
after incubation with digitonin, using the 0.4% Trypan Blue exclu-
sion method, and no loss of viability was observed (data not
shown). The supernatant was then removed and replaced for
selected times with serumless media containing the same con-
centration of the isotope at room temperature. In test groups, the
replacement media also contained 35 M gentamicin. Explants
were incubated for 5 min or 1 h. The cultures were then exposed
to hand-help UV light (254 nm) at a 2 cm distance for 2.5 min. The
supernatant was then replaced with ice cold 2 mM dithiothreitol
(DTT) in serumless media to terminate the reaction for 5 min. The
DTT solution was then replaced with Laemmli buffer and 10%
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SDS-PAGE was performed. After gel drying, autoradiography was
performed (Jo et al., 1992). Photoactivity of the probe was con-
firmed by exposing the probe to serum GTP-binding protein and
performing photolysis with a hand-held UV lamp. Negative con-
trols were performed by treating explants for 48 h with 200 M
gentamicin, thereby selectively killing HCs, 2 days prior to a
second 5 min gentamicin treatment and G-protein labeling. Posi-
tive controls were performed by treating cardiac fibroblasts with
1 M bradykinin for 5 min, which activates an approximately 42 kD
G subunit.
Immobilized Al3-chelate affinity chromatography
Immobilized Al3-chelate affinity chromatography was performed
as described by Shoemaker and Haley (1993). Iminodiacetic acid
Sepharose 6B fast flow resin (1–2 ml; Sigma) was placed in a 5 ml
syringe and washed with 10 ml of distilled water. Ten milliliters of
50 mM AlCl3 was then passed through the column and washed
with 10–15 ml of distilled water. The column was then equilibrated
with 100 mM ammonium acetate at pH 5.9. 40 basal turn explants
previously photolabeled after treatment for 1 h with gentamicin
were then homogenized in a small glass douncer containing 1 ml
100 mM ammonium acetate at pH 5.9. Negative controls con-
tained explants treated only with serumless media. Homogenates
were then passed through the charged resin column. The column
was washed consecutively with 15 ml of 100 mM ammonium
acetate at pH 5.9, 5 ml of 100 mM ammonium acetate containing
0.5 M NaCL at pH 5.9, and then 5 ml of 100 mM ammonium
acetate at pH 5.9. Photolabeled proteins bound to the charged
resin beads were then eluted with 5 ml of 100 mM ammonium
acetate containing 10 mM KH2PO4 at pH 8.0. The purified, pho-
tolabeled peptides eluted in the phosphate wash were pooled and
then precipitated with 1:1 (500 l) isopropanol and tRNA (10 g/
ml) at 20 °C. After overnight precipitation and pelleting, the
pellets were solubulized using 1 Tris–glycine sample buffer
(Bio-Rad Laboratories, Chicago, IL, USA). Fifteen percent SDS-
PAGE was then performed using two parallel wells for the exper-
imental group and one well for the appropriate negative and
positive controls. Pre-stained standards (Bio-Rad Laboratories)
were used as well. The region containing the labeled protein was
then cut from one experimental lane using a stainless steel scal-
pel, and the protein extracted for MALDI analysis.
MALDI mass spectrometry
The gel piece was transferred to a 0.5 ml Eppendorf tube.
Distilled water (0.4 ml) was added, the tube vortexed for 1 min,
and the liquid discarded. Digestion buffer (25 mM ammonium
bicarbonate, pH 8) was added, the mixture vortexed for 1 min,
and the liquid discarded. Modified sequence grade trypsin
(0.5 g; Promega) dissolved in digestion buffer (Promega,
Madison, WI, USA) was then added to cover the gel piece at a
trypsin concentration of 0.1 g/l while minimizing evaporation
of the digestion solution and Na and K salt precipitation. The
gel piece was then incubated with agitation at 30 °C overnight.
The supernatant was then transferred to a new Eppendorf tube
using a gel loading pipet tip. The gel piece was then re-extracted
using 60% acetonitrile/0.01% TFA (enough to cover the piece) by
agitating for 20 min at 30 °C. The extract was then combined with
the previous supernatant. This was repeated twice, while keeping
the volume as low as possible. The pooled supernatants were
then dried to approximately 10 l using a lyophilizer. The MALDI
ion trap mass spectrometer is composed of an external MALDI ion
source and a modified Finnigan ITMS electronics kit. Laser de-
sorption/ionization was carried out at wavelength of 355 nm with
10 ns duration pulses. The matrix solution consisted of 2,5-dihy-
droxybenzoic acid (DHB) in 1:1 (v/v) ACN/H2O (2 dilution of a
saturated solution of DHB in 1:1 (v/v) ACN/H2O). The mass spec-
troscopy samples were prepared by mixing 1 l of sample solution
with 1 l of matrix solution. The instrument was mass calibrated
once a week.
Procedure for protein identification
The peptide mixture produced by in-gel trypsin digestion of
protein was analyzed directly by MALDI ion trap mass spec-
troscopy without further chromatographic separation or treat-
ment. Trypsin peaks were used as internal standards to cali-
brate the mass spectrometer and enable high resolution spec-
trometry with an error of 0.5 kDa mass units. After the mass
spectroscopy peptide map was inspected, the mass units were
entered and searched against predicted trypsin digest frag-
ments of proteins in a mammalian protein database (Genbank,
Oxford Molecular Group, Mountain Valley, CA, USA) using the
program ProFound (Genomic Solutions, Lansing, MI, USA) with
a tolerance of 0.2 kDa. Peaks that were not one third above
background and those that matched the blank gel were not
included. The search was carried out with constraints that
include the mass range of the protein, the cleavage specificity
of the digesting enzyme, and the originating species of the
protein. A positive control sample containing 10 g/ml of human
Ras (Sigma) and a blank sample were analyzed as well.
Data analysis
Comparison of HC number after treatment with gentamicin and
with different inhibitors was performed by using repeated mea-
sures ANOVA followed by LSD post hoc test (Stat View 5.0).
Differences associated with P-values	0.05 were considered to
be statistically significant. All data are presented as mean
S.E.
RESULTS
In vitro ototoxicity
Phalloidin–rhodamine-stained control explants showed
the normal configuration of a single row of IHCs and
three rows of OHCs in the area of the basal turn after
48 h in culture (Fig. 1a). All of the HCs exhibited normal
stereociliary morphology. Equivalent basal turn explants
treated with 35 M gentamicin for 48 h showed signifi-
cantly reduced HC survival (Fig. 1b). The first row of
OHCs showed the greatest degree of damage, followed
by the second row of OHCs and then the third row. Total
loss of OHCs was about 50%. The IHCs were the most
resistant to damage, showing only scattered loss.
General G-protein inhibitor GDP-S protected
auditory HCs
Treatment of basal turn explants with the general G-protein
inhibitor GDP-S (1 mM) for 12 h prior to gentamicin
exposure and during exposure for 48 h to 35 M gentami-
cin resulted in a significant increase (P	0.01) in the num-
ber of surviving OHCs as well as in the number of HCs that
appeared morphologically normal compared with the
group with gentamicin alone (Figs. 1c, 2a).
ADP-S did not protect the HCs against gentamicin
toxicity (P0.216; data not shown). Explants treated for
48 h with 1 mM GDP-S alone, also appeared normal
(data not shown).
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G-protein photoaffinity labeling in the OC after
exposure to gentamicin
To determine the molecular weight of G-proteins that might
be activated by gentamicin, basal turn explants were
loaded with [32P]GTP-AA and then treated with genta-
micin for 5 min or 1 h in the dark. After UV exposure, SDS-
PAGE and autoradiography revealed that one or more ap-
proximately 21 kDa G-proteins were activated by gentamicin
at both 5 min and 1 h (Fig. 3a). Negative controls revealed
minimal photolabeling at 21 kDa in explants exposed to oto-
toxin-free media (Fig. 3a). Cardiac fibroblasts treated with
1 M bradykinin for 5 min showed a approximately 42 kD
labeled protein (data not shown). Pre-incubation of OC sam-
ples with 1 m GDP-S prevented incorporation of the probe,
while ADP-S did not. Explants pre-treated with 200 M
gentamicin for 48 h in order to specifically destroy HCs prior
to photolabeling experiments showed little or no incorporation
of the azido-GTP probe during a subsequent gentamicin
exposure, suggesting that the observed 21 kDa GTP binding
is related to HCs (Fig. 3b).
Isolation and purification of 21 kDa band and MALDI
analysis
Basal turn explants were loaded with [32P]GTP- AA as
above and then treated with gentamicin for 1 h in the dark.
After UV exposure, phosphorylated proteins were captured
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Fig. 1. a) Rhodamine–phalloidin staining of a cultured normal p5 rat OC basal turn explant. Note intact stereocilia of OHCs and IHCs. The OHCs (1–3)
are in the uppermost three rows while the IHCs (I) are in the lowermost row. b) Representative p5 rat OC basal turn explant after 48h in vitro exposure
to gentamicin. Note the extensive loss of OHCs with the IHCs being the most resistant to damage and the third row of OHCs being the second most
resistant. c) Representative explant treated with GDP-S (1 mM) prior to and during exposure to gentamicin (35 M) in vitro. There was a significant
(P	0.01) improvement in OHC survival compared with gentamicin alone. d) Explant treated with the Ftase-inhibitor B581 (50 M) prior to and during
gentamicin exposure. Significant (P	0.01) protection of OHCs was observed. e) Explant treated with the Ftase-inhibitor FTI-277 (10 M) prior to and
during gentamicin exposure in vitro. Again, significant (P	0.01) OHC protection was observed.
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by Al3 IMAC and then eluted prior to resolution in two
adjacent lanes by SDS-PAGE. Gel pieces were cut out in
the 20–25 kDA range from one lane and trypsin digested
prior to MALDI analysis. Autoradiography of the adjacent
lane on the gel confirmed photolabeling of 21 kDa GTP
binding protein (Fig. 3c).
High resolution MALDI analysis of the trypsin digested
sample revealed a peptide map dominated by several peaks.
When the peak spectrum was used to search the protein
database, the optimal match was with c-H-Ras-p21, with
46% sequence coverage. The peptide peaks that matched
c-H-p21-Ras produced a z score of 1.66 (P	0.05). MALDI of
purified Ras positive control followed by database analysis
showed the highest match to an H-Ras p21 protein mutant
with Gln 61 replaced by Leu. The sequence coverage was
69% with a z score of 2.38 (P	0.05).
The farnesyl-transferase inhibitors B581 and FTI-277
protect auditory HCs
To determine the functional role of Ras activation in gen-
tamicin-mediated OHC death, basal turn explants were
pre-treated with 50 M B581 or 10 M FTI-277 for 12 h
prior to exposure to gentamicin (in addition to the inhibitor).
We observed a significant (P	0.05) increase in OHC sur-
vival in explants treated with either inhibitor, compared with
explants treated with gentamicin alone (Figs. 1d, e, 2b). In
the case of FTI-277 we observed a dose-dependent effect
in OHC survival (Fig. 2c). The lowest dose of FTI-277
(1 M) was associated with significantly more OHC loss
than observed with gentamicin alone (P	0.01; Fig. 2c).
However, at the highest dosages (5 and 10 M) significant
OHC protection occurred (P	0.01; Fig. 2c). Explants
a.
b.
G
D
P
-ß
S
+
G
en
t.
0
5
10
15
20
25
30
35
40
C
o
n
tr
o
l
O
H
C
s
p
er
 t
en
 I
H
C
s
G
en
t.
C
o
n
tr
o
l
*
0
5
10
15
20
25
30
35
O
H
C
's
p
er
 t
en
 I
H
C
's
B
5
8
1
+
G
en
t.
C
o
n
tr
o
l
C
o
n
tr
o
l
G
en
t.
*
c.
d.
14
16
18
20
22
24
26
28
30
co
n
tr
o
l
3
5
µM
 g
en
t
2
µ
M
 F
T
I 
+
 g
en
t
5
µ
M
 F
T
I 
+
 g
en
t
1
0
µ
M
 F
T
I 
+
 g
en
t
O
H
C
s
p
er
 t
en
 I
H
C
s
1
µ
M
 F
T
I 
+
 g
en
t
12
10
* *
*
0
5
10
15
20
25
30
35
O
H
C
s
p
er
 t
en
 I
H
C
s
U
O
1
2
6
U
O
1
2
6
 +
 G
en
t.
3
5
µM
 g
en
t
co
n
tr
o
l
*
+
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concentration (1 M; P	0.05) of FTI-277 compared with gentamicin alone, whereas at the highest concentrations (5, 10 M) FTI-277 protected HCs
from gentamicin toxicity (P	0.01). * Indicates a significant difference from gentamicin alone. d) Average basal turn OHC survival after exposure to
gentamicin and/or the MEK inhibitor UO126 (1 M). There was a significant decrease in OHC survival after treatment with U0126 alone (P	0.01), and
also when comparing gentamicin and U0126 versus gentamicin (P	0.01).  Indicates significant difference from control culture, * indicates a
significant difference from gentamicin alone.
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treated with 10 M FTI-277 alone were normal (data not
shown).
FTI-277 attenuates JNK signaling in ototoxicity
To determine whether the protection of OHCs by Ras
inhibition using FTI-277 was associated with an attenu-
ation of the JNK signaling pathway, explants were either
exposed to gentamicin or pretreated with 10  M FTI-
277 and then exposed to gentamicin plus FTI-277 for
20 h prior to phospho-c-Jun immuno-labeling. Control
explants, exposed to culture medium alone, showed no
detectable immunostaining of HC nuclei (Fig. 4b). Basal
turn explants of the OC exposed to 35 M gentamicin for
20 h and immunostained showed strong phospho-c-Jun
immunolabeling of OHC nuclei, and a lesser labeling of
IHC nuclei (Fig. 4d). There was no labeling of supporting
cell nuclei. Explants treated with FTI-277 prior to and
during gentamicin treatment showed little or no immu-
nostaining (Fig. 4f). Because of the reduced time of
exposure to gentamicin, all explants when stained with
phalloidin–rhodamine showed one row of IHCs and
three rows of OHCs (Fig. 4a, c, e).
a.
5’ 60’ 60’
21kDa
Gent      Contr
21 kDa
21 kDa
b.
No
OHCs OHCs
Contr Epi Gent
1        2     3
c.
Fig. 3. a) Autoradiography of proteins from control P5 rat OC basal turn explants and explants treated with 35 M gentamicin for 5 min or 1 h. Explants
were exposed to UV light to induce photochemical cross-linking of [ 32P] GTP AA to activated G-proteins prior to SDS-PAGE, which revealed a 21
kDa protein. Negative control explants maintained only in culture media for 1 h revealed minimal photolabeling at 21 kDa. b) Autoradiography of P5
rat OC explants exposed to gentamicin. Explants pre-treated with 200 M gentamicin for 48 h in order to specifically kill HCs and then allowed to
recover for 48 h prior to a 5 min treatment with gentamicin and photolabeling showed minimal incorporation of the azido-GTP probe (lane 1). Normal
explants (lanes 2, 3) showed GTP binding of 21 kDa protein in response to gentamicin. c) Autoradiography of SDS-PAGE after Al3 IMAC purification
of proteins from OC explants. There is no protein labeling in the negative control explants or in explants treated with 1 M epinephrine. Proteins from
explants treated with gentamicin showed strong labeling at 21 kDa. An identical lane was cut out and protein extracted for MALDI analysis.
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Auditory HCs and MEK: studies with U0126
To determine whether Ras signaling via MEK and the ERK
MAPK played a role in OHC toxicity, basal turn explants were
exposed to gentamicin with or without a MEK inhibitor. Inhib-
itor control explants were exposed to the MEK inhibitor alone.
Treatment of basal turn explants with the MEK inhibitor
UO126 alone resulted in significant (P	0.05) OHC loss (Fig.
2d). When gentamicin was added, both OHCs and IHCs
were completely lost (P	0.001; Fig. 2d). The control com-
pound U0124 had no effect on normal or gentamicin-treated
OC (data not shown).
DISCUSSION
We have previously shown that the growth factor FGF-2,
whose receptor often activates G-proteins, protects OHCs
against ototoxins (Low et al., 1996). As a preparatory step
in assessing the role of G-proteins in this protection, we
treated basal turn OC explants with a general G-protein
inhibitor prior to and during gentamicin exposure. Against
our expectations, explants treated with GDP-S revealed
significantly improved HC survival, even in the absence of
FGF-2, suggesting that inhibition of G protein activity itself
can protect HCs from this toxin.
b.
d.
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I
01
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c.
I
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I
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I
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d.
I
01
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03
f.
I
01
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Control
Gentamicin
Gentamicin+FTI-277
Phalloidin Phospho-c-Jun
Fig. 4. a, b) Basal turn p5 OC explants maintained in culture medium alone (Control) for 32 h show the normal configuration of the OC in phalloidin
labeled images (a), and no phospho-c-Jun immunolabeling (b). O1, O2, O3: row 1, 2, and 3 of OHCs, I: IHCs. Bar20 m. c, d) Basal turn explant
maintained in culture for 12 h and then exposed to 35 M gentamicin for 20 h shows normal morphology in the phalloidin-labeled image (c), and strong
staining of the OHC nuclei and weaker labeling of IHC nuclei by the phospho-c-Jun antibody (d). Bar20 m. e, f) Basal turn explant pretreated with
FTI-277 (10  M) for 12 h and FTI-277 plus gentamicin (35 M) for 20 h shows normal OC in the phalloidin-rhodamine image (e), and little or no
phospho-c-Jun immunolabeling (f). Bar20 m.
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Intracellular GDP-S presumably inactivates G-pro-
teins which would otherwise initiate cell death after expo-
sure to gentamicin. The fact that ADP-S, a structural
analog of GDP-S with similar charge, did not significantly
improve HC survival after gentamicin exposure supports
the interpretation that GDP-S acts through intracellular
inhibition of G-protein activity as opposed to extracellular
neutralization of the toxin or a nonspecific intracellular
activity of nucleotides. [ 32P]GTPAA photolabeling stud-
ies indicated that, relative to untreated explants, gentami-
cin-treated explants exhibit increased GTP binding activity
by proteins in the 21 kDa range, such as members of the
Ras or Rho families.
Exposure to stressful stimuli induces small G-protein
activation in other cell systems. Interestingly, this activa-
tion can be either protective or damaging depending upon,
for one thing, the length of stress application. For example,
5–10 min of exposure to free radicals in Jurkat T-cells has
been shown to induce Ras activation directly by redox
modification of amino acid residue Cys118 (Lander et al.,
1997) which in turn results in Ras binding to the effector
PI3K (Deora et al., 1998). The serine-threonine kinase
Akt/PKB can subsequently be activated leading to in-
creased BAD phosphorylation, resulting in initial protection
of the cell (Basu et al., 1998; Joneson and Bar-Sagi, 1999).
Longer term exposure to stress has been shown to initiate
cellular damage via small G-protein activation and the JNK
pathway (Kharbanda et al., 2000). For example, Cos-7
cells transfected with dominant negative Ras are protected
from apoptosis induced by long-term exposure to ceramide
(Basu et al., 1998).
The results of MALDI and peptide matching indicated
that H-Ras is activated in the OC after brief toxin exposure.
Other isoforms of Ras in addition to members of the Rho
family do not appear to be activated at this early time,
according to the MALDI analysis. The potential role of this
Ras activation in HC toxicity was explored with Ftase
inhibitors.
Ftase inhibitors block the activity of Ras by inhibiting
the prenylation that is required for membrane insertion of
Ras, which is in turn necessary for downstream Ras sig-
naling (see Leonard, 1997 for a review). Within the Ras
superfamily, Ftase inhibition is specific to Ras proteins,
since Rho isoforms (with the exception of RhoB) and Rac
are geranylgeranylated rather than farnesylated. FTI-277
does not affect geranylgeranylation at concentrations up to
at least 10 M, the highest dose used in the present study,
suggesting that the effects of Ftase inhibitors within the
Ras superfamily are limited to Ras isoforms. However, it
should be noted that in addition to Ras, other proteins such
as lamin B, -transducin, RhoB, and CENPs are also
farnesylated. It is therefore possible that inhibition of these
proteins is responsible for the protection of HCs from gen-
tamicin. The lack of prior data linking them to HCs or to
ototoxicity makes this less likely.
Interestingly, a dose response study of HCs to FTI-277
showed that HC survival is adversely affected at low con-
centrations (1 M) of this reagent, but that protection oc-
curs at higher dosages (5–10 M). This suggests that Ras
pathways contributing to HC survival are selectively inhib-
ited at lower concentrations while Ras-dependent path-
ways contributing to HC death are selectively inhibited at
higher concentrations (10 M). Potentially relevant to this
issue, FTI-277 has been shown to have a dose-dependent
specificity for the different Ras isoforms, H-Ras, N-Ras
and K-Ras. H-Ras processing is inhibited at concentra-
tions as low as 10 nM of FTI-277 and is almost completely
blocked at 3 M (Casey et al., 1989; Lerner et al., 1995).
Inhibition of N-Ras processing requires 5 M of FTI-277
while complete inhibition of K-Ras requires 10 M (Casey
et al., 1989; Lerner et al., 1995). Thus, the data from our
dose-response study suggest that low concentrations of
FTI-277 may enhance OHC death through inhibition of
H-Ras, while higher concentrations of FTI-277 may protect
OHCs through inhibition of K-Ras and/or N-Ras.
This concept is supported by mounting data in the
literature which indicate that the different Ras isoforms
generate specific functional endpoints (Wolfman, 2001).
Disruption of the gene encoding K-Ras results in a lethal
embryonic phenotype while H-Ras and N-Ras knockouts
are viable, indicating significant differences between the
isoforms in regulating development (Umanoff et al., 1995;
Johnson et al., 1997; Koera et al., 1997; Esteban et al.,
2001). H-Ras is frequently involved in MEK/ERK activation
via Raf 1. K-Ras appears to be more involved in Rac
activation than the other isoforms. Overexpression of K-
Ras increases Rac/cdc42 accumulation, which in turn
leads to more membrane ruffling and faster cell migration
when compared with cells transfected with G12V-H-Ras
(Walsh and Bar-Sagi, 2001). N-Ras appears to provide
steady-state survival signals through PI3K, Akt and mito-
chondrial Bcl-2 family proteins (Wolfman and Wolfman,
2000).
We found that MEK inhibitors also influenced HC sur-
vival, proving to be toxic to OHCs even without gentamicin.
When they were used in combination with gentamicin,
strong potentiation of toxicity was observed, and all OHCs
and IHCs were lost. This suggests that normal OHCs and
IHCs depend upon MEK activation for survival, and that
MEK activity opposes cell death during toxin treatment.
Ras is often an upstream activator of MEK, suggesting the
Ras/Raf/MEK/ERK MAPK pathway. However, the obser-
vation that the MEK inhibitor alone but not FTI-277 alone is
toxic to OHCs indicates that there may be other upstream
activators of MEK such as protein kinase C, Rap1 or RafB
(via crkL and C3G) that act independently of Ras (McCu-
brey et al., 2000) in normal HCs. In damaged HCs, H-Ras
may contribute to MEK activation as it does in other cell
types (Yamamoto et al., 1999).
With respect to HC damage, we recently observed
inhibition of gentamicin-induced HC damage with Clostrid-
ium difficile toxin B, a potent inhibitor of Rho GTPases
including Rac/cdc42 (Bodmer et al., 2002a). Rac/cdc42
could provide a link between K-Ras and JNK signaling.
Other possible downstream targets of Ras exist, including
p38 and PI3K. However we have found that relatively high
concentrations of inhibitors of these pathways did not re-
A. Battaglia et al. / Neuroscience 122 (2003) 1025–10351032
duce gentamicin ototoxicity in our model system (data not
shown).
A model for Ras activity in the gentamicin-exposed
OHC can be inferred from our data and from the results of
others (Fig. 5). In this model, initial ototoxin exposure
activates H-Ras, which then promotes HC survival through
increased activation of MEK and the ERK MAPK. Thus,
inhibition of H-Ras with low concentrations of FTI-277, or
inhibition of MEK with UO126 enhances OHC death. Pro-
longed ototoxin exposure activates K-Ras, which promotes
HC death via increased activity of JNK. Thus, inhibition of
K-Ras with high concentrations of FTI-277, inhibition of
Rac/cdc42 (Bodmer et al., 2002b) or inhibition of JNK
(Pirvola et al., 2000; Bodmer et al., 2002b) can protect HCs
from aminoglycoside exposure. The observation that high-
dose FTI-277 decreases c-Jun phosphorylation in HCs
due to gentamicin exposure is consistent with this
interpretation.
As noted above, Ras has been shown to have variable
functions depending on the environmental and genetic
conditions of a cell. Ras is not alone in having variable
functions. Dual functions for the regulation of cell survival,
proliferation, differentiation or apoptosis have been shown
for c-Myc (Evan and Littlewood, 1998), and c-Fos (Colotta
et al., 1992). The evidence in this study points toward Ras
playing roles both in HC survival and cell death.
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